The UK and US have agreed to a major trade agreement that will keep zero tariffs on UK medicine products going into the US market.
The Terms of the Accord
Under the terms of the agreement, the UK has committed to boost funding on medicines through the NHS. This move ensures that import taxes on these crucial goods will be held at zero for a timeframe of the next three years.
This development is in response to recent statements to hike duties on patented pharmaceutical products, with increases floated up to one hundred percent.
"This arrangement with the United Kingdom bolsters the global environment for innovative medicines and introduces long-overdue balance to American-British medicine commerce," a statement noted.
Commercial Significance
Drugs constitute one of the Britain's most significant goods shipped to the US, which is by far the largest destination for large British pharmaceutical firms.
Statistics indicate that in the one-year period leading up to the third quarter, the UK shipped drugs worth over eleven billion pounds to the US. This value represented nearly one-fifth of British export trade in that timeframe.
"This agreement safeguards jobs, increases investment and facilitates the UK to become a global hub for biotech and pharma," a minister commented.
Key NHS Changes
The pact includes several notable pledges from the British government:
- Higher Cost Ceiling: The UK will increase the cost ceiling at which it judges new treatments to be unaffordable by twenty-five percent.
- Higher Drug Budget: There is a aim to double overall public funding on medicines from 0.3% of GDP to 0.6% over the next decade.
- Rebate Cap: The amount pharmaceutical firms must refund to the NHS to prevent overspending will be limited at fifteen percent. In the past, repayments topped 20%.
Broader Context
The deal follows a ongoing dispute between the drug companies and the British authorities over spending levels and NHS adoption.
These tensions were intensified by claims that American customers were charged significantly more for the same drugs than people in the UK and Europe.
Over the last 18 months, several major drug company projects in the UK have been delayed or cancelled, while multi-billion-dollar funding commitments have been directed toward projects in the United States.
A senior figure stated that the NHS had to increase expenditure on medicines, noting that its expenditure on drugs had decreased as a proportion of its total funding over the past decade.
